{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:52:38Z","timestamp":1762865558069},"reference-count":4,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T00:00:00Z","timestamp":1224720000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For the approval of cinacalcet hydrochloride, five clinical trials have been performed excluding pharmacokinetic studies for healthy volunteers and hemodialysis patients. An early phase II dose\u2010finding study was started for regular hemodialysis patients with secondary hyperparathyroidism from a daily dose of 12.5\u2003mg cinacalcet and increasing 25\u2003mg up to 50\u2003mg for 9\u2003weeks. A placebo\u2010controlled double\u2010blind three dose\u2013finding study (late phase II study) was then conducted. By this trial, an adequate initial dose of cinacalcet was determined as 25\u2003mg daily, and the placebo\u2010controlled double\u2010blind study (phase III study) was started using this initial dose. Two long\u2010term (1\u2003year) phase III open trials were also conducted during and after these phase II and III studies. The results of two double\u2010blind trials (phase II and phase III) and safety profiles of cinacalcet in all Japanese clinical trials for approval are summarized in this article.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2008.00625.x","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:53:43Z","timestamp":1245664423000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Study of Cinacalcet in Japan"],"prefix":"10.1111","volume":"12","author":[{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00556.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm534"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00516.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00631.x"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2008.00625.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2008.00625.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T21:48:44Z","timestamp":1694468924000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2008.00625.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":4,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1744-9987.2008.00625.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00625.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}